Paclitaxel

CHEMBL428647 Phase 4 Onaylandı Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
853.9 g/mol
LogP
2.5
Phase
4

A taxane chemotherapy drug that stabilizes microtubules in dividing cells, preventing them from completing cell division and causing cancer cell death. It is used to treat a wide range of cancers including breast, ovarian, lung, and Kaposi's sarcoma.

Moleküler Ağırlık

853,9000 g/mol

LogP

2,50

TPSA

221,00 Ų

Lipinski RO5

Başarısız

Terapötik Alanlar

Etki Mekanizması

Disrupts microtubule dynamics by binding to tubulin, preventing the formation of the mitotic spindle and arresting cell division at metaphase. This induces apoptosis in rapidly dividing cells.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Disrupts microtubule dynamics by binding to tubulin, preventing the formation of the mitotic spindle and arresting cell division at metaphase. This induces apoptosis in rapidly dividing cells.

2D Yapı

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O

InChI

InChI=1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1

Molecular Formula

C47H51NO14

HBD / HBA

4 / 14

Döndürülebilir Bağlar

14

Ağır Atomlar

62

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

A taxane chemotherapy drug that stabilizes microtubules in dividing cells, preventing them from completing cell division and causing cancer cell death. It is used to treat a wide range of cancers including breast, ovarian, lung, and Kaposi's sarcoma.

Disrupts microtubule dynamics by binding to tubulin, preventing the formation of the mitotic spindle and arresting cell division at metaphase. This induces apoptosis in rapidly dividing cells.

Yes, Paclitaxel is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL428647. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 36314. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.